Form PTO-1390 TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A FILING UNDER 35 U.S.C. 371


INTERNATIONAL APPLICATION NO. | INTERNATIONAL FILING DATE October 6, 2003 PCT/EP2003/011027

EXPRESS MAIL LABEL NO.: EL 979108831 US ATTORNEY'S DOCKET NUMBER: 04156.0012U1 U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/530,224 PRIORITY DATE CLAIMED October 4, 2002

TITLE OF INVENTION:

PRODUCS WITH HUMAN GLYCOSYLATION PATTERN			
		NT(S) FOR DO/EO/US: SANDIG, Karsten WINKLER, Uwe MARX and Tobias WERMELINGER	
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1.		This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.	
2.	\boxtimes	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.	
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.	
4.		The US has been elected (Article 31).	
5.		A copy of the International Application as filed (35 U.S.C. 371(c)(2))	
		a. is attached hereto (required only if not communicated by the International Bureau).	
		b. has been communicated by the International Bureau.	
		c. is not required, as the application was filed in the United States Receiving Office (RO/US).	
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))	
		a. is attached hereto.	
		b. has been previously submitted under 35 U.S.C. 154(d)(4).	
7.		Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))	
		a. are attached hereto (required only if not communicated by the International Bureau).	
		b. have been communicated by the International Bureau.	
		c. have not been made; however, the time limit for making such amendments has NOT expired.	
		d. have not been made and will not be made.	
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).	
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).	
10.		An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).	
	Items	s 11 to 20 below concern document(s) or information included:	
11.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.	
12.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.	
13.		A preliminary amendment.	
14.		An Application Data Sheet under 37 CFR 1.76.	
15.		A substitute specification.	
16.		A power of attorney and/or change of address letter.	
17.	Ø	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825. The contents of the paper copy and the computer-readable form of the Sequence Listing submitted herewith are the same and include no new matter, as required by 37 C.F.R. 1.821(f).	
18.		A second copy of the published international application under 35 U.S.C. 154(d)(4).	
19		A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4)	

20. Other items or information:



ATTORNEY DOCKET NO. 04156.0012U1 EXPRESS MAIL LABEL NO. EL979108831 US PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
SANDIG, et al.) Art Unit: unassigned	
Application No. 10/530,224) Examiner: unassigned	
International Filing Date: October 6, 2003) Confirmation No. 1743	
For: HIGH YIELD HETEROLOGOUS EXPRESSION CELL LINES FOR)	
EXPRESSION OF GENE PRODUCTS WITH HUMAN GLYCOSYLATION PATTERN)))	

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 NEEDLE & ROSENBERG, P.C.

Customer Number 23859

October 13, 2005

Sir:

In response to the Notification to Comply with Requirements mailed September 28,

2005 in the above-referenced patent application, enclosed are:

- 1. a diskette with the Sequence Listing in computer readable form as required by 37 CFR 1.821(e);
- 2. a paper copy of the Sequence Listing (13 pages)
- 3. a copy of the "Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures."

ATTORNEY DOCKET NO. 04156.0012U1 EXPRESS MAIL LABEL NO. EL979108831 US Application No. 10/530,224

Please be advised that the contents of the paper and the computer readable form of the Sequence Listing submitted herewith in the above-identified patent application are the same and include no new matter, as required by 37 C.F.R. 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

No fee is believed to be due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

Lizette M. Fernandez Registration No. 46,692

NEEDLE & ROSENBERG, P.C. Customer Number 23859 (678) 420-9300 (678) 420-9301 (fax)